Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DG50 | ISIN: IL0011839383 | Ticker-Symbol:
NASDAQ
02.10.25 | 19:35
4,325 US-Dollar
-1,26 % -0,055
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ALPHA TAU MEDICAL LTD Chart 1 Jahr
5-Tage-Chart
ALPHA TAU MEDICAL LTD 5-Tage-Chart

Aktuelle News zur ALPHA TAU MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial3
27.08.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer2
11.08.Alpha Tau Medical Ltd.: Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update212- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical...
► Artikel lesen
23.06.Alpha Tau files to sell 3.46M ordinary shares by selling shareholders3
17.06.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln
28.05.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
19.05.Alpha Tau Medical GAAP EPS of -$0.111
19.05.Alpha Tau Medical Ltd.: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update247- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive...
► Artikel lesen
19.05.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
12.05.Alpha Tau Medical ernennt neues Vorstandsmitglied5
12.05.Alpha Tau Medical Ltd.: Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors1
06.05.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
28.04.Oramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical9
28.04.Oramed investiert 36,9 Millionen US-Dollar in Alpha Tau Krebstherapie29
28.04.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
28.04.Alpha Tau Medical Ltd.: Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals7
28.04.Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical523Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies...
► Artikel lesen
02.04.Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma280JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA...
► Artikel lesen
12.03.Alpha Tau Medical Ltd.: Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update791- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive...
► Artikel lesen
19.11.24Alpha Tau Medical Ltd.: Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update150- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1